PDF herunterladen
Open Access
CC BY 4.0 · Facial Plast Surg
DOI: 10.1055/a-2764-3062
Original Research

First Insights on the Upcoming Role of Next-generation PLLA-LASYNPRO in Aesthetic and Regenerative Medicine: A Survey of Experts—the PLLA-LASYNPRO Rationale

Autor*innen

  • Dario Bertossi

    1   Department of Surgical Sciences, Section of Oral and Maxillofacial Surgery, University of Verona, Verona, Italy

  • Maurizio Cavallini

    2   Executive Committee of Agorà, Italian Society of Aesthetic Medicine, Milan, Italy

  • Alessandra Camporese

    3   International School of Aesthetic Medicine, Fondazione Internazionale Fatebenefratelli, Rome, Italy

  • Roberto Dell'Avanzato

    4   Private Practice, Milan, Italy

  • Nicola Kefalas

    5   Rigenera Lab, Turin, Italy

  • Enrico Massidda

    6   Università Niccolò Cusano, Rome, Italy

  • Marco Papagni

    2   Executive Committee of Agorà, Italian Society of Aesthetic Medicine, Milan, Italy

  • Mariagrazia Patalano

    7   Private Practice, Studio Mariagrazia Patalano, Messina, Italy

  • Sandro Quartucci

    8   Saba Clinic, Rome, Italy

  • Monica Renga

    2   Executive Committee of Agorà, Italian Society of Aesthetic Medicine, Milan, Italy

  • Adriano Santorelli

    9   Adriano Santorelli & Partners Private Practice, Naples, Italy

  • Chantal Sciuto 

    2   Executive Committee of Agorà, Italian Society of Aesthetic Medicine, Milan, Italy

  • Gloria Trocchi

    10   Pathology Isola Tiberina Hospital - Gemelli Isola, Rome, Italy

Funding Information This work was supported by Nordberg Medical, NC.
Weitere Informationen
Auch verfügbar auf
  Lizenzen und Reprints

Abstract

Introduction

Injectable collagen stimulators have traditionally been linked to inflammatory foreign-body reactions (FBR) as a mechanism of action. However, the next-generation PLLA-LASYNPRO microspheres, contained in the CE-marked JULÄINE medical device, may represent a paradigm shift. Preclinical data suggest these microspheres can promote collagen and extracellular matrix (ECM) regeneration with minimal inflammatory response.

Objectives and Hypotheses

This study aimed to evaluate the scientific soundness and clinical relevance of a non-inflammatory mechanism of action for PLLA-LASYNPRO. The central hypothesis was that design and manufacturing innovations could enable effective biostimulation while reducing inflammation and long-term tissue reactions.

Study Design

A structured expert board meeting was convened to assess the rationale and implications of this emerging mechanism. The process included a preliminary survey and an in-person consensus meeting involving multidisciplinary specialists in aesthetic and regenerative medicine.

Methods

On January 24, 2025, 13 experts in aesthetic medicine, dermatology, and plastic surgery participated in a board meeting held in Milan, Italy. Scientific literature and preclinical data were reviewed in advance. Discussions were organized around biophysical characteristics, tissue integration, inflammatory profile, and safety considerations.

Results

The board considered the non-inflammatory mechanism of PLLA-LASYNPRO both biologically plausible and clinically promising. Key differentiating features included particle morphology, lack of excipients, and manufacturing purity. The panel highlighted the potential to reduce chronic inflammation, a known limitation of traditional collagen stimulators. Early clinical impressions supported this hypothesis, although prospective data are still forthcoming.

Conclusion

This manuscript presents the consensus of a multidisciplinary board on the rationale for PLLA-LASYNPRO in aesthetic and regenerative medicine. It forms the first part of a two-paper series. The second manuscript will provide practical clinical guidance for the deep dermal administration of PLLA-LASYNPRO and real-world use of JULÄINE.

Keywords

earlier-generation poly-L-lactic acid - extracellular matrix regeneration - foreign body response - injectable collagen stimulators - expert board - PLLA-LASYNPRO - skin quality

Contributors' Statement

D.B.: conceptualization, methodology, supervision, validation, visualization, writing—review and editing; M.C.: conceptualization, methodology, supervision, validation, writing—review and editing; A.C.: conceptualization, data curation, methodology, resources, supervision, validation, visualization, writing—review and editing; R.D.: conceptualization, methodology, supervision, validation, writing—review and editing; N.K.: conceptualization, methodology, resources, supervision, validation, visualization, writing—review and editing; E.M.: conceptualization, data curation, methodology, resources, supervision, validation, visualization; M.F.P.: conceptualization, methodology, supervision, validation, writing—review and editing; M.P.: conceptualization, data curation, methodology, resources, validation, visualization, writing—review and editing; S.Q.: conceptualization, data curation, methodology, resources, supervision, validation, visualization, writing—review and editing; M.R.: conceptualization, methodology, resources, supervision, validation, visualization, writing—review and editing; A.S.: conceptualization, data curation, methodology, resources, supervision, validation, visualization, writing—review and editing; C.S.: conceptualization, methodology, resources, supervision, validation, visualization, writing—review and editing; G.T.: conceptualization, methodology, supervision, validation, visualization, writing—review and editing.




Publikationsverlauf

Eingereicht: 06. August 2025

Angenommen nach Revision: 03. Dezember 2025

Artikel online veröffentlicht:
27. Februar 2026

© 2026. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/).

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA